Payment overview · 2025
General Payments
$524.88
28 reported records · 12 companies
Healthcare provider profile · identity verified
Karla D Mccann, DO
Allopathic & Osteopathic Physicians|Family Medicine · FORD CITY, PA · NPI 1730162538
Verified facts
What the public records show
CMS Open Payments records show Karla D Mccann, DO received $524.88 in general payments during 2025 across 28 reported records.
GlaxoSmithKline, LLC. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $159.39 | 30.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.99 | 20.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.17 | 11.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.85 | 7.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.46 | 7.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.41 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.77 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.07 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.09 | 3.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.94 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.88 | 2.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.86 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $524.88 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $159.39 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 136 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
168 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
136 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
142 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
176 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 909 | 187 |
| Atorvastatin Calcium | Atorvastatin Calcium | 814 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 758 | 167 |
| Omeprazole | Omeprazole | 585 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 571 | 114 |
| Lisinopril | Lisinopril | 490 | 124 |
| Losartan Potassium | Losartan Potassium | 408 | 89 |
| Gabapentin | Gabapentin | 396 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 328 | 76 |
| Furosemide | Furosemide | 322 | 74 |
| Metformin Hcl | Metformin Hcl | 317 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 284 | 61 |
| Simvastatin | Simvastatin | 284 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 257 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 248 | 84 |
| Glimepiride | Glimepiride | 241 | 58 |
| Potassium Chloride | Potassium Chloride | 227 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 57 |
| Benazepril Hcl | Benazepril Hcl | 218 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 218 | 49 |
| Montelukast Sodium | Montelukast Sodium | 205 | 50 |
| Eliquis | Apixaban | 195 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 49 |
| Ozempic | Semaglutide | 176 | 33 |
| Synthroid | Levothyroxine Sodium | 168 | 41 |
| Allopurinol | Allopurinol | 162 | 37 |
| Sertraline Hcl | Sertraline Hcl | 150 | 36 |
| Meloxicam | Meloxicam | 146 | 32 |
| Lorazepam | Lorazepam | 142 | 42 |
| Trulicity | Dulaglutide | 142 | 28 |
| Famotidine | Famotidine | 139 | 32 |
| Prednisone | Prednisone | 139 | 86 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 136 | 29 |
| Bupropion Xl | Bupropion Hcl | 134 | 31 |
| Metformin Hcl Er | Metformin Hcl | 124 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 44 |
| Celecoxib | Celecoxib | 116 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 25 |
| Irbesartan | Irbesartan | 113 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 106 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 103 | 91 |
| Ezetimibe | Ezetimibe | 98 | 22 |
| Alendronate Sodium | Alendronate Sodium | 97 | 20 |
| Xarelto | Rivaroxaban | 95 | 15 |
| Trazodone Hcl | Trazodone Hcl | 89 | 21 |
| Valsartan | Valsartan | 87 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 15 |
| Carvedilol | Carvedilol | 84 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 83 | 17 |
| Methylprednisolone | Methylprednisolone | 82 | 69 |
| Atenolol | Atenolol | 78 | 13 |
| Cefuroxime | Cefuroxime Axetil | 78 | 41 |
| Jardiance | Empagliflozin | 77 | 15 |
| Buspirone Hcl | Buspirone Hcl | 75 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 16 |
| Bumetanide | Bumetanide | 74 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 65 |
| Solifenacin Succinate | Solifenacin Succinate | 74 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 18 |
| Warfarin Sodium | Warfarin Sodium | 71 | 14 |
| Spironolactone | Spironolactone | 70 | 18 |
| Nystatin | Nystatin | 68 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | 15 |
| Alprazolam | Alprazolam | 65 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 11 |
| Ondansetron Odt | Ondansetron | 64 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 16 |
| Baclofen | Baclofen | 57 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 13 |
| Pregabalin | Pregabalin | 54 | 12 |
| Tramadol Hcl | Tramadol Hcl | 54 | 21 |
| Gemfibrozil | Gemfibrozil | 53 | suppressed |
| Clonazepam | Clonazepam | 52 | 17 |
| Finasteride | Finasteride | 51 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 39 |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 46 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 14 |
| Fluconazole | Fluconazole | 44 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | 12 |
| Donepezil Hcl | Donepezil Hcl | 39 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 34 |
| Clonidine | Clonidine | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | 11 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 11 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Invokana | Canagliflozin | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 18 |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Premarin | Estrogens, Conjugated | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 11 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 27 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Repaglinide | Repaglinide | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Mesalamine | Mesalamine | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Ibu | Ibuprofen | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 13 |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Primidone | Primidone | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Etodolac | Etodolac | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Epinephrine | Epinephrine | 14 | 13 |
| Mupirocin | Mupirocin | 14 | 12 |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tretinoin | Tretinoin | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Xolair | Omalizumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $524.88 · 28 records | GlaxoSmithKline, LLC. | ABRYSVO, Auvelity, COMIRNATY, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, MOUNJARO, NURTEC ODT, ONZETRA XSAIL, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error